{"id":24932,"date":"2022-10-25T16:59:00","date_gmt":"2022-10-25T08:59:00","guid":{"rendered":"https:\/\/flcube.com\/?p=24932"},"modified":"2025-02-02T17:04:24","modified_gmt":"2025-02-02T09:04:24","slug":"giant-biogene-set-for-ipo-on-hong-kong-stock-exchange-to-raise-funds-for-expansion","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=24932","title":{"rendered":"Giant Biogene Set for IPO on Hong Kong Stock Exchange to Raise Funds for Expansion"},"content":{"rendered":"\n

China-based medical aesthetics company Giant Biogene Holding Co., Ltd (HKG: 2367<\/a>) has announced plans to conduct an initial public offering (IPO) of 22.61 million shares on the Hong Kong Stock Exchange. The offering price is set to range from HKD 24.3 (USD 3.10) to HKD 27.7 (USD 3.53) per share. Goldman Sachs and CICC will act as the co-sponsors of the transaction, which is expected to go live on November 4. The proceeds will be used to expand the company’s research and development (R&D) team, enhance R&D facilities, boost manufacturing capabilities, and strengthen omni-channel marketing and the marketing network.<\/p>\n\n\n\n

Company Background and Market Position<\/strong>
Founded in 2000, Giant Biogene is one of China’s leading professional skin care companies, specializing in biological active ingredients, particularly recombinant collagen. The company’s recombinant collagen product, COLLGENE, ranked third in the industry in terms of sales in 2021. Giant Biogene was the first in the country to obtain a recombinant collagen medical device license. In 2021, the company generated RMB 1.55 billion (USD 212 million) in revenues and RMB 828 million (USD 113.3 million) in net profits.<\/p>\n\n\n\n

Future Development Plans<\/strong>
The funds raised from the IPO will support Giant Biogene’s strategic initiatives to enhance its R&D capabilities and expand its manufacturing facilities. The company aims to further strengthen its market position by investing in omni-channel marketing and expanding its marketing network. This move underscores Giant Biogene’s commitment to innovation and growth in the medical aesthetics sector.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based medical aesthetics company Giant Biogene Holding Co., Ltd (HKG: 2367) has announced plans to…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[20,3498,3497,100],"class_list":["post-24932","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-finance","tag-giant-biogene","tag-hkg-2367","tag-medical-aesthetics"],"yoast_head":"\nGiant Biogene Set for IPO on Hong Kong Stock Exchange to Raise Funds for Expansion - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based medical aesthetics company Giant Biogene Holding Co., Ltd (HKG: 2367) has announced plans to conduct an initial public offering (IPO) of 22.61 million shares on the Hong Kong Stock Exchange. The offering price is set to range from HKD 24.3 (USD 3.10) to HKD 27.7 (USD 3.53) per share. Goldman Sachs and CICC will act as the co-sponsors of the transaction, which is expected to go live on November 4. The proceeds will be used to expand the company's research and development (R&D) team, enhance R&D facilities, boost manufacturing capabilities, and strengthen omni-channel marketing and the marketing network.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=24932\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Giant Biogene Set for IPO on Hong Kong Stock Exchange to Raise Funds for Expansion\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=24932\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-25T08:59:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-02T09:04:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24932#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24932\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Giant Biogene Set for IPO on Hong Kong Stock Exchange to Raise Funds for Expansion\",\"datePublished\":\"2022-10-25T08:59:00+00:00\",\"dateModified\":\"2025-02-02T09:04:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24932\"},\"wordCount\":257,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Finance\",\"Giant Biogene\",\"HKG: 2367\",\"Medical aesthetics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24932#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24932\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=24932\",\"name\":\"Giant Biogene Set for IPO on Hong Kong Stock Exchange to Raise Funds for Expansion - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-10-25T08:59:00+00:00\",\"dateModified\":\"2025-02-02T09:04:24+00:00\",\"description\":\"China-based medical aesthetics company Giant Biogene Holding Co., Ltd (HKG: 2367) has announced plans to conduct an initial public offering (IPO) of 22.61 million shares on the Hong Kong Stock Exchange. The offering price is set to range from HKD 24.3 (USD 3.10) to HKD 27.7 (USD 3.53) per share. Goldman Sachs and CICC will act as the co-sponsors of the transaction, which is expected to go live on November 4. The proceeds will be used to expand the company's research and development (R&D) team, enhance R&D facilities, boost manufacturing capabilities, and strengthen omni-channel marketing and the marketing network.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24932#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24932\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24932#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Giant Biogene Set for IPO on Hong Kong Stock Exchange to Raise Funds for Expansion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Giant Biogene Set for IPO on Hong Kong Stock Exchange to Raise Funds for Expansion - Insight, China's Pharmaceutical Industry","description":"China-based medical aesthetics company Giant Biogene Holding Co., Ltd (HKG: 2367) has announced plans to conduct an initial public offering (IPO) of 22.61 million shares on the Hong Kong Stock Exchange. The offering price is set to range from HKD 24.3 (USD 3.10) to HKD 27.7 (USD 3.53) per share. Goldman Sachs and CICC will act as the co-sponsors of the transaction, which is expected to go live on November 4. The proceeds will be used to expand the company's research and development (R&D) team, enhance R&D facilities, boost manufacturing capabilities, and strengthen omni-channel marketing and the marketing network.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=24932","og_locale":"en_US","og_type":"article","og_title":"Giant Biogene Set for IPO on Hong Kong Stock Exchange to Raise Funds for Expansion","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=24932","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-10-25T08:59:00+00:00","article_modified_time":"2025-02-02T09:04:24+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=24932#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=24932"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Giant Biogene Set for IPO on Hong Kong Stock Exchange to Raise Funds for Expansion","datePublished":"2022-10-25T08:59:00+00:00","dateModified":"2025-02-02T09:04:24+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=24932"},"wordCount":257,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Finance","Giant Biogene","HKG: 2367","Medical aesthetics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=24932#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=24932","url":"https:\/\/flcube.com\/?p=24932","name":"Giant Biogene Set for IPO on Hong Kong Stock Exchange to Raise Funds for Expansion - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-10-25T08:59:00+00:00","dateModified":"2025-02-02T09:04:24+00:00","description":"China-based medical aesthetics company Giant Biogene Holding Co., Ltd (HKG: 2367) has announced plans to conduct an initial public offering (IPO) of 22.61 million shares on the Hong Kong Stock Exchange. The offering price is set to range from HKD 24.3 (USD 3.10) to HKD 27.7 (USD 3.53) per share. Goldman Sachs and CICC will act as the co-sponsors of the transaction, which is expected to go live on November 4. The proceeds will be used to expand the company's research and development (R&D) team, enhance R&D facilities, boost manufacturing capabilities, and strengthen omni-channel marketing and the marketing network.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=24932#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=24932"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=24932#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Giant Biogene Set for IPO on Hong Kong Stock Exchange to Raise Funds for Expansion"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24932","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24932"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24932\/revisions"}],"predecessor-version":[{"id":24934,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24932\/revisions\/24934"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24932"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24932"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24932"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}